Local and systemic effects of an allogeneic tumor cell vaccine combining transgenic human lymphotactin with interleukin-2 in patients with advanced or refractory neuroblastoma
- 1 March 2003
- journal article
- clinical trial
- Published by American Society of Hematology in Blood
- Vol. 101 (5) , 1718-1726
- https://doi.org/10.1182/blood-2002-08-2493
Abstract
We developed a method to generate dendritic cells (DCs) from mouse embryonic stem (ES) cells. We cultured ES cells for 10 days on feeder cell layers of OP9, in the presence of granulocyte-macrophage colony-stimulating factor in the latter 5 days. The resultant ES cell–derived cells were transferred to bacteriologic Petri dishes without feeder cells and further cultured. In about 7 days, irregularly shaped floating cells with protrusions appeared and these expressed major histocompatibility complex class II, CD11c, CD80, and CD86, with the capacity to stimulate primary mixed lymphocyte reaction (MLR) and to process and present protein antigen to T cells. We designated them ES-DCs (ES cell–derived dendritic cells), and the functions of ES-DCs were comparable with those of DCs generated from bone marrow cells. Upon transfer to new dishes and stimulation with interleukin-4 plus tumor necrosis factor α, combined with anti-CD40 monoclonal antibody or lipopolysaccharide, ES-DCs completely became mature DCs, characterized by a typical morphology and higher capacity to stimulate MLR. Using an expression vector containing the internal ribosomal entry site–puromycinN-acetyltransferase gene or a Cre-lox–mediated exchangeable gene-trap system, we could efficiently generate ES cell transfectants expressing the products of introduced genes after their differentiation to DCs. ES-DCs expressing invariant chain fused to a pigeon cytochrome C epitope presented the epitope efficiently in the context of Ek. We primed ovalbumin (OVA)–specific cytotoxic T lymphocytes in vivo by injecting mice with ES-DCs expressing OVA, thus demonstrating immunization with ES-DCs genetically engineered to express antigenic protein. The methods may be applicable to immunomodulation therapy and gene-trap investigations of DCs.Keywords
This publication has 33 references indexed in Scilit:
- Lymphotactin cotransfection enhances the therapeutic efficacy of dendritic cells genetically modified with melanoma antigen gp100Gene Therapy, 2002
- Adenovirus-mediated lymphotactin gene transfer improves therapeutic efficacy of cytosine deaminase suicide gene therapy in established murine colon carcinomaGene Therapy, 2000
- Adenoviral Vectors Expressing Lymphotactin and Interleukin 2 or Lymphotactin and Interleukin 12 Synergize to Facilitate Tumor Regression in Murine Breast Cancer ModelsHuman Gene Therapy, 1999
- T Helper Cell Type 1–associated and Cytotoxic T Lymphocyte–mediated Tumor Immunity Is Impaired in Interleukin 4–deficient MiceThe Journal of Experimental Medicine, 1999
- Interleukin-2 Gene-Modified Allogeneic Tumor Cells for Treatment of Relapsed NeuroblastomaHuman Gene Therapy, 1998
- GD2 oligosaccharide: target for cytotoxic T lymphocytes.The Journal of Experimental Medicine, 1995
- Use of Murine Models of Cytokine-Secreting Tumor Vaccines to Study Feasibility and Toxicity Issues Critical to Designing Clinical TrialsJournal of Immunotherapy, 1995
- In vitro anti‐tumor activity of eosinophils from cancer patients treated with subcutaneous administration of interleukin 2. Role of interleukin 5International Journal of Cancer, 1993
- An Eosinophil-Dependent Mechanism for the Antitumor Effect of Interleukin-4Science, 1992
- Enhancement of monoclonal antibody dependent cell mediated cytotoxicity by IL2 and GM‐CSFBritish Journal of Haematology, 1989